Study S002014

Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes vs Best Medical Treatment

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT02041234
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: COMPLETED
Enrollment: 40
Start: 2014-02
Primary completion: 2020-12
Lead sponsor: Khoo Teck Puat Hospital
Conditions: Type II Diabetes in Subjects BMI 27 to 32
Interventions: PROCEDURE:Roux-en-Y Gastric Bypass (RYGB); DRUG:Incretin analogues; DRUG:Xenical; DRUG:SGLT2 inhibitors; DRUG:DPP-4 Inhibitors
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Number of subjects achieving HBA1c of 6% without diabetic medication [at 12 month after randomisation]
Number of subjects achieving systolic BP <130mm hg without antihypertension medication [12 months post randomisation]
number of subjects achieving LDL level of <100mg/dl without lipid lowering medication [12 months post randomisation]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0028961	Roux-en-Y gastric bypass versus best medical treatment for type 2 diabetes mellitus in adults with body mass index between 27 and 32 kg/m2: A 5-year randomized controlled trial. Cheng A, Diabetes research and clinical practice	2022	Randomized trial	PMID 35513159 DOI	cites ClinicalTrials.gov:NCT02041234; registry reference DERIVED:35513159